Callable Multi Barrier Reverse Convertible

Symbol: LAAHDU
ISIN: CH1424869274
Issuer:
UBS
Trade

Chart

    
    

SIX Structured Products trading

SIX Structured Products Bid Ask Notation
Please note that data is only available after start of trading.
Price Time-delayed price
23.06.26
22:15:00
- %
- %
CHF
Volume
0
0
nominal
Trading hours for this product: 9:15 – 17:15

Performance

Closing prev. day 73.55
Diff. absolute / % 1.75 +2.38%

Determined prices

Last Price 67.10 Volume 20,000
Time 13:35:32 Date 10/06/2026

More Product Information

Core Data

Name Callable Multi Barrier Reverse Convertible
ISIN CH1424869274
Valor 142486927
Symbol LAAHDU
Quotation in percent Yes
Coupon p.a. 10.50%
Coupon Premium 10.50%
Type Multi Barrier Reverse Convertibles
SVSP Code 1230
Barrier reached Yes (Novo Nordisk AS (B) - 02/03/2026)
Exercise type American
Currency Swiss Franc
First Trading Date 28/04/2025
Date of maturity 28/10/2026
Last trading day 21/10/2026
Settlement Type Cash payout
IRS 871m Not applicable
Currency safeguarded Yes
Pricing Clean
Issuer UBS

Key data

Ask Price (basis for calculation) 76.5000
Maximum yield 34.76%
Maximum yield p.a. 99.91%
Sideways yield -2.10%
Sideways yield p.a. -6.04%

market maker quality Date: 22/06/2026

Average Spread 1.39%
Last Best Bid Price 73.55 %
Last Best Ask Price 74.55 %
Last Best Bid Volume 100,000
Last Best Ask Volume 100,000
Average Buy Volume 100,000
Average Sell Volume 100,000
Average Buy Value 71,622 CHF
Average Sell Value 72,622 CHF
Spreads Availability Ratio 99.31%
Quote Availability 99.31%

Underlyings

Name Novo Nordisk AS (B) Roche PS
ISIN DK0062498333 CH1499059983
Price 41.6275 EUR 325.2000 CHF
Date 23/06/26 22:59 23/06/26 17:31
Cap 421.25 DKK 254.40 CHF
Distance to Cap -121.3 70.4
Distance to Cap in % -40.44% 21.67%
Is Cap Level reached No No
Barrier 231.688 DKK 139.92 CHF
Distance to Barrier 17.4625 184.88
Distance to Barrier in % 7.01% 56.92%
Is Barrier reached Yes No

Please wait...
The data push was deactivated due to a timeout. Please click "Refresh page" to continue.